Navigation Links
Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
Date:12/5/2007

THE WOODLANDS, Texas, Dec. 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that dosing has commenced in a Phase 2a clinical trial with LX6171, an oral drug candidate for the treatment of cognitive impairment associated with disorders such as Alzheimer's disease, schizophrenia, and vascular dementia. The initial stage of the trial will assess the bioavailability of a new oral-suspension formulation in healthy elderly subjects with a second stage evaluating safety, tolerability and cognitive effects in elderly subjects with age-associated memory impairment (AAMI).

"AAMI is an emerging area of clinical research and offers an expedient population for obtaining proof-of-concept with a drug candidate, like LX6171, that has a broad range of potential applications in the area of cognitive disorders," said Philip M. Brown, M.D., J.D., vice president of clinical development at Lexicon. "Following the strength of the Phase 1 data indicating LX6171 is generally well tolerated, we have adopted a two-stage strategy for Phase 2a in order to transition to our new oral suspension formulation and to assess for improvements in a variety of cognitive dimensions as we enter the elderly population."

Phase 2 Study Design

The initial stage of the trial will assess the bioavailability of a single-dose oral suspension in 16 healthy elderly subjects. The second stage will be a randomized, double-blind, placebo-controlled evaluation of safety, tolerability, and cognitive effects in approximately 120 subjects over four weeks. This stage is anticipated to include three groups of 40 subjects each, exploring two dose levels with a placebo control. Exact dose levels for the second stage wi
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... /PRNewswire-iReach/ -- It is no secret that Americans have an ... obese gyms and supplement companies are in line to make ... related to dietary issues and a lack of physical activity ... glandular problem or even a vitamin deficiency. (Photo: ... a lack of vitamin b12 . The vitamin is ...
(Date:5/20/2013)... May 20, 2013   National Community Pharmacists Association ... , RPh, MBA issued the following statement today regarding ... Medicare Part D "preferred pharmacy" drug plans , ... the plan,s lowest advertised co-payments: (Logo:  ... and MedPAC , 16 U.S. Senators ...
(Date:5/20/2013)... 20, 2013 /PRNewswire-iReach/ -- Today at American Society ... Christine Ginocchio discussed Specific Technologies blood ... identification of microorganisms producing bloodstream infection. Dr. Ginocchio ... the Division of Infectious Disease Diagnostics at North ... non-sectarian health system. (Photo: http://photos.prnewswire.com/prnh/20130520/CG16829 ...
Breaking Medicine Technology:USB12Shots.com Discusses the Possibility of B12 Shots for Weight Loss 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3
... 1 InterMune, Inc. (Nasdaq: ITMN ) today announced ... InterMune, will present at the Fourth Annual JMP Securities Healthcare ... 3:30 p.m. EDT. , To access a live ... may log on to the investor relations page of InterMune,s ...
... announced today that it has entered into a binding agreement ... Fovea has a portfolio of three clinical compounds, a unique ... the eye diseases. The deal is valued to a total ... milestone payments related to the progress of the clinical compounds. ...
Cached Medicine Technology:Fovea Pharmaceuticals to be Acquired by sanofi-aventis 2
(Date:5/21/2013)... of sudden infant death syndrome (SIDS) is five times ... study finds. British researchers noted that bed-sharing increases ... drink, use illegal drugs or smoke. They advised that ... infant death in developed countries, would drop dramatically if ... the United States, all parents are advised to not ...
(Date:5/21/2013)... The warning images Brussels proposes to include on tobacco ... the desired impact on smokers because they only find ... Commission wants to improve the efficacy of its anti-smoking ... that make a stronger emotional impact., These are some ... of Personality, Evaluation and Psychological Treatment at the University ...
(Date:5/21/2013)... known for their health benefits, and the subtropical ... drugs are delivered to specific tumor cells. , ... create nanoparticles using natural lipids derived from grapefruit, ... drug delivery vehicles. UofL scientists Huang-Ge Zhang, D.V.M., ... (May 21, 2013), published their findings in ...
(Date:5/21/2013)... Representatives with Hammerhead Bicycles announced today that their re-launched bike ... achieved its overall goal of becoming a standalone brand. , ... Bicycles from a house brand to a standalone bike brand,” ... that the bike shop will go forward as Switchback ... 29er and 650b. , “The bike shop will ...
(Date:5/21/2013)... 21, 2013 TheBeautyPlace.com helps brides to ... features a Big Day Kit including all the essentials ... to shine on their Wedding Day. , TheBeautyPlace.com features ... about on their Wedding Day. Flowers blooming and warmer ... of wedding season. From Memorial Day to October, brides ...
Breaking Medicine News(10 mins):Health News:Bed-Sharing Raises SIDS Risk Fivefold, Study Finds 2Health News:Warning images for cigarette packs proposed by Europe do not make enough emotional impact 2Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Hammerhead Bicycles Now a Standalone Brand 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3
... Itamar Medical ... ... Medicine, Mayo Clinic, Rochester, MN Dr. Peter Friberg, Sahlgrenska University ... Mr. Israel Schreiber, President and CEO, Itamar Medical ...
... reduced heart risks after angioplasty/stenting, but raised bleeding risks ... -- A new anti-clotting drug might one day challenge Plavix, ... procedures to open blocked coronary arteries, a new study suggests. ... -- notably those who had had a prior stroke, were ...
... ORLANDO, FL A North Carolina team of doctors, ... up with a way to provide faster, more effective ... require expensive drugs or fancy new equipment. But it ... on everyone involved to move treatment forward empowering ...
... Calif., Nov. 4 Consistent implementation of,proven ... to a Kaiser,Permanente (KP) abstract, published this ... in Orlando, Florida. The researchers followed ... to Kaiser Permanente emergency departments in Northern,California ...
... research suggests , , SUNDAY, Nov. 4 (HealthDay News) ... typically need open-heart surgery might someday have a new, ... , The balloon is inserted percutaneously (through the skin), ... said. In a new study, the procedure -- not ...
... risk of major cardiovascular events by 19, percent, significantly ... ... bleeding, TOKYO and INDIANAPOLIS, Nov. 4 ... investigational,antiplatelet agent prasugrel produced a highly significant 19 percent,reduction in relative ...
Cached Medicine News:Health News:How Early Can We Detect Cardiovascular Disease Less Expensively ... Even in Childhood? 2Health News:New Anti-Clotting Drug Shows Promise in Heart Patients 2Health News:New Anti-Clotting Drug Shows Promise in Heart Patients 3Health News:RACE: a statewide model of better, faster heart attack care 2Health News:RACE: a statewide model of better, faster heart attack care 3Health News:Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions 2Health News:Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions 3Health News:Balloon Valve May Be Alternative to Open-Heart Surgery 2Health News:Balloon Valve May Be Alternative to Open-Heart Surgery 3Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 2Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 3Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 4Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 5Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 6Health News:In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack 7
... imaging camera system designed for scientific ... megapixel digital cameras provides high-resolution, full-color ... on a PC via its Firewire ... previewing capability is accompanied by automatic ...
... digital output. Three-chip color camera for brightfield, ... of high-quality color video cameras give you ... need for an efficient viewing experience. These ... of your specimen that can be easily ...
... The PM20 is a fully automatic fluorescence ... quality photomicrographs of even the most difficult ... the new PM20 system provide solution to ... addition to their automatic exposure control, the ...
... photomicrography system that greatly simply taking ... difficult specimens. Designed with real life in ... to the complex problem of fluorescence photomicrography. ... the system utilizes special programs designed to ...
Medicine Products: